See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
South America
Social Media
Natural Disasters
Trade War
Tariffs
Donald Trump
Soccer
Formula 1
Premier League
Taxes
Tennis
European Union
Published • loading... • Updated

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)

Summary by Ground News
Roctavian (valoctocogene roxaparvovec) granted conditional marketing authorization (CMA) for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5) Maintains Orphan Drug Designation (ODD) in the EU Providing 10-years of market exclusivity.

2 Articles

All
Left
Center
1
Right
PR NewswirePR Newswire
Center

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization...

·United States
Read Full Article
BioMarinBioMarin

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)

Maintains Orphan Drug Designation (ODD) in the EU Providing 10-years of Market Exclusivity Significant Benefit Over Existing Therapies for Patients with Severe Hemophilia A in EU Based on EMA...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

BioMarin broke the news in on Wednesday, August 24, 2022.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

European Commission

European Commission

Eu

Eu

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal